TimothyGMurrayMDMBA, FACS

Ophthalmology • South Miami, FL

Cataract Related, Retinal Disease, Ocular Oncology

Physician

Join to view full profile

Dr. Murray is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Murray's full profile

Already have an account?

Office
6705 S Red Rd
Ste 412
South Miami, FL 33143
Phone+1 305-487-7470

Fax+1 786-567-4380

Summary

Timothy G. Murray, MD, MBA is currently the Founding Director/CEO of Ocular Oncology and Retina of Miami Florida. Dr. Murray’s early academic career was focused on the development of an integrated Ocular Oncology service at the Bascom Palmer Eye Institute, Sylvester Comprehensive Cancer Center. In 2012, Dr. Murray founded the Ocular Oncology and Retina Center in Miami, Florida. Dr. Murray continues as Tenured, Professor Emeritus in Ophthalmology and Radiation Oncology with the Bascom Palmer Eye Institute. Dr. Murray’s focus on founding the private Ocular Oncology and Retina Center was related to his ongoing pursuit of excellence in clinical care particularly targeted on advanced imaging and treatment technologies. Dr. Murray’s Ocular Oncology and Retina Center continues to provide International, National and Regional care for patients with life- and sight-threatening complex eye disease.
Dr. Murray’s primary focus is in ocular oncology and retinal disease. Dr. Murray has been involved in the evaluation of novel treatment approaches for ocular melanoma, retinoblastoma, vascular tumors and has utilized basic and translational laboratory studies to enhance our understanding of the molecular and pathogenetic mechanisms for tumor development. Dr. Murray’s interest in new evaluation and treatment technologies has been pivotal in the marked advancements in melanoma and retinoblastoma management in the United States and internationally.
Dr. Murray is a graduate of the Johns Hopkins School of Medicine in the combined BA/MD program in 1985, completed his Residency and Chief Residency at the University of California, San Francisco in Ophthalmology and completed both a surgical and research Fellowship in vitreoretinal surgery and ocular oncology at the Eye Institute, Medical College of Wisconsin. Dr. Murray expanded his health care focus when he graduated with a Master’s in Business Administration (MBA) in 2005.
Dr. Murray has published over 300 peer reviewed articles.

Education & Training

University of MiamiMBA, Health Care, 2003 - 2005
Medical College of Wisconsin Affiliated HospitalsFellowship, Surgical Retina and Vitreous, 1990 - 1991
Med Coll Wisconsin Affil HospsPost-Doctoral Fellowship, 1989 - 1990
University of California (San Francisco)Chief Residency, Ophthalmology, 1988 - 1989
University of California (San Francisco)Residency, Ophthalmology, 1986 - 1989
MedStar Health (Baltimore)Internship, Internal Medicine, 1985 - 1986
Johns Hopkins University School of MedicineClass of 1985
Johns Hopkins UniversityB.A, 1981

Certifications & Licensure

CA State Medical License 1987 - Present
FL State Medical License 1991 - 2025
WI State Medical License 1989 - 2014
American Board of Ophthalmology Ophthalmology

Awards, Honors, & Recognition

Top Doctors:South Florida Castle Connolly, 2018
Top Doctors: Florida Castle Connolly, 2018
America's Top Doctors Castle Connolly, 2009-2018
America's Top Doctors for Cancer Castle Connolly, 2005-2018
Senior Achievement Award American Academy of Ophthalmology, 2007
Senior Achievement Award American Society of Retinal Specialists, 2005
Achievement Award Recipient American Academy of Ophthalmology, 2001
Phi Beta Kappa Johns Hopkins School of Medicine, 1985
Nevada State AMA Award Recipient 1982
Biology Honors Programs Johns Hopkins University, 1981
Honors Johns Hopkins University, 1981
Super Doctor SuperDoctors.com
Top MD Consumers Checkbook
Fellow (FACS) American College of Surgeons
Fellow (FAAO) American Academy of Ophthalmology
Join now to see all

Clinical Trials

Role of Intravitreal Aflibercept Injection for the Treatment of Radiation Maculopathy Start of enrollment: 2015 Oct 01
Completed
Phase 2

Publications & Presentations

PubMed

70 citations
Supraselective intra-arterial chemotherapy: Evaluation of treatment-related complications in advanced retinoblastoma
Lejla Vajzovic, Timothy G. Murray, Mohammad Ali Aziz-Sultan, Amy C. Schefler, Stacey Q Wolfe
Clinical Ophthalmology. 2011-02-10
4 citations
Alphabet Soup: Clinical Pearls for the Retina Specialist-Ocular Toxicity of Advanced Antineoplastic Agents in Systemic Cancer Care.
Victor M Villegas, Timothy G Murray
Ophthalmology. Retina. 2021-12-01
14 citations
Distinguishing Torpedo Maculopathy From Similar Lesions of the Posterior Segment
Victor M. Villegas, Stephen G. Schwartz, Harry W. Flynn, Hilda Capo, Audina M. Berrocal
Ophthalmic Surgery, Lasers & Imaging Retina. 2014-05-01

Journal Articles

Bilateral Ocular Manifestations of Aggressive Cutaneous Metastatic Melanoma.
Cebulla CM, Alegret A, Feun L, Markoe AM, Hess DJ, Murray TG, Retinal Cases Brief Reports. 2008;2(4):286-288
Echographic Localization of Periocular Carboplatin for Advanced Retinoblastoma.
Alegret AM; Cebulla CM, Dubovy SR, Mutapcic L, Hess DJ, Murray TG, Retinal Cases Brief Reports
Photodynamic Therapy And Vitrectomy For A Large Optic Nerve Hemangioma With Neovascularization and Retinal Detachment: A Clinicopathologic Correlation.
Alegret AM, Cebulla CM, Dubovy SR, Mutapcic L, Hess DJ, Murray TG, Retinal Cases Brief Reports
Effects of SU1498, an Inhibitor of Vascular Endothelial Growth Factor Receptor-2, in a Transgenic Murine Model of Retinoblastoma.
Cebulla CM, Jockovich ME, Boutrid H, Piña Y, Ruggeri M, Jiao S, Bhattacharya SK, Feuer WJ, Murray TG, Open Ophthalmol J. 2008.2(1):62-67
Ocular tumors: update on pharmacology, therapeutics, and ocular imaging.
Schefler AC, Jockovich ME, Lossos IS, Toledano S, Feilmeier M, Murray TG, Retinal Physician
Cancer mortality in the United States by education level and race.
Albano JD, Ward E, Jemal A, Anderson R, Cokkinides VE, Murray TG, Henley J, Liff J, Thun MJ, Natl Cancer Inst. 2007 Sept 19;99(18):1384-94
Clinical features, management strategies, and visual acuity outcomes of Candida endophthalmitis following cataract surgery.
Gregori NZ, Flynn HW Jr, Miller D, Scott IU, Davis JL, Murray TG, Williams B Jr, Ophthalmic Surg Lasers Imaging. 2007 Sep-Oct;38(5):378-85
Motility assessment and clinical outcomes of a magnetically integrated microporous implant.
Miller DM, Murray TG, Suarez F, Cicciarelli NL, Swords GG, Ophthalmic Surg Lasers Imaging. 2007 Jul-Aug;38(4):339-41
Historical and modern approaches to chemotherapy for retinoblastoma: A review.
Schefler AC, Jockovich ME, Toledano S, Murray TG, Expert Review in Ophthalmology; 2006: 1: 83-95
Subconjuctival antibiotics in the treatment of endophthalmitis managed without vitrectomy.
Smiddy WE, Smiddy RJ, Ba’Arath B, Flynn HW, Murray TG, Feuer WJ, Miller D, Retina 2005; 25(6): 751-758
Outcomes of surgery for retinal detachment associated with proliferative vitreoretinopathy using perfluoro-n-octane: A multicenter study.
Scott IU, Flynn HW Jr, Murray TG, Feuer WJ, Am J Ophthalmol 2003;136:454-463
Endogenous fungal retinitis in a patient with acute lymphocytic leukemia manifesting as uveitis and optic nerve lesions.
Song A, Dubovy SR, Berrocal AM, Murray TG, Arch Ophthalmol 2002;120:1754-1756
Outcomes and complications associated with giant retinal tear management using perfluoro-n-octane.
Scott IU, Murray TG, Flynn HW Jr, Feuer WJ, Schiffman JC, and the Perfluoron Study Group, Ophthalmology 2002;109:1828-1833
Reply to letter on Histoplasma capsulatum var. capsulatum.
Davis JL, Miller D, Gonzales CA, Scott IU, Murray T, Ophthalmology 2002;109:218-219
Corneal graft survival and intraocular pressure control after penetrating keratoplasty and glaucoma drainage device implantation.
Arroyave CP, Scott IU, Fantes FE, Feuer WJ, Murray TG, Ophthalmology 2001;108:1978-1985
Echography of retinoblastoma: histopathologic correlation and serial evaluation after globe-conserving radiotherapy or chemotherapy.
Roth DB, Scott IU, Murray TG, Kaiser PK, Feuer WJ, Hughes JR, Rosa RH Jr, J Pediatr Ophthalmol Strabismus 2001;38:136-143
Traumatic macular hole. Observations, pathogenesis, and results of vitrectomy surgery.
Johnson RN, McDonald HR, Lewis H, Grand MG, Murray TG, Mieler WF, Johnson MW, Boldt HC, Olsen KR, Tornambe PE, Folk JC, Ophthalmology 2001;108:853-857
Routine neuroimaging in retinoblastoma for the detection of intracranial tumors.
Duncan JL, Scott IU, Murray TG, Gombos DS, van Quill K, O’Brien JM, Arch Ophthalmol 2001;119:450-452
Surgical removal of submacular choroidal neovascularization: a clinicopathologic study and factors influencing outcomes.
Corey RP, Scott IU, Flynn HW Jr, Rosa RH Jr, Murray TG, Ophthalmic Surg Lasers 2001;32:406-418
Experimental models for transcleral laser thermotherapy of ocular tumors.
Parel J-M, Qiu H, Manns F, Fujiwara E, Lee W, Salas N, Hayden B, Lee E, Dubovy S, Murray TG, Florida Lions Eye Bank, 2001 Annual Report, pp.10-11
Outcomes of vitreoretinal surgery for complications of branch retinal vein occlusion.
Amirikia A, Scott IU, Murray TG, Flynn HW Jr., Smiddy WE, Feuer WJ, Ophthalmology 2001;108:372-376
Siblings of retinoblastoma patients: are we underestimating their risk?
Smith JH, Murray TG, Fulton L, O’Brien JM, Am J Ophthalmol 2000; 129(3): 396-398
Evaluation of chemoprophylaxis in patients with unilateral retinoblastoma with high-risk features on histopathologic examination.
Uusitalo MS, Van Quill KR, Scott IU, Matthay KK, Murray TG, O’Brien JM, Arch Ophthalmol 2001;119:41-48
Development and characterization of a rodent model of methanol-induced retinal and optic nerve toxicity.
Eells JT, Henry MM, Lewandowski MF, Seme MT, Murray TG, Neurotoxicology 2000;21(3):321-330
Echographic features of medulloepithelioma.
Foster RE, Murray TG, Byrne SF, Hughes JR, Gendron BK, Ehlies FJ, Nicholson DH, Am J Ophthalmol 2000;130:364-366
Join now to see all

Books/Book Chapters

Chapter: Management of intraocular tumors.
Harbour JW, Murray TGEditors: Albert D.
Chapter: Complications of enucleation surgery. COMS Report 2.
COMS GroupEditors: Franklin RM.Kugler Publications, New York
Chapter: Ocular ferromagnetic hyperthermia.
Page 473 - 478Murray TG, Mieler WF, Steeves RAEditors: Bornfeld N, Gragoudas ES, Hopping W, Lommatzsch PK, Wessing A, Zografos L.Kugler Publications, West Germany
Chapter: The lowest effective dose of tissue plasminogen activator for fibrinolysis of postvitrectomy fibrin.
Page 353 - 361Boldt HC, Abrams GW, Murray TG, Han DP, Mieler WFEditors: Stirpe M.Ophthalmic Communications Society, New York
Chapter: Flow Cytometry of Diagnostic Vitrectomy Specimens.
Page 315 - 318Davis T, Ruiz P, Viciana A, Thompson WS, Murray TGEditors: Nussenblatt RB, Whitcup SM, Caspi RR, Gery I.Elsevier, Amsterdam
Chapter: Posterior Uveal Melanomas.
Page 382 - 393Murray TG, Mieler WF, Lewandowski MFEditors: Margo CE, Mames RN, Hamed LM.WB Saunders Company
Chapter: Immunology of Ocular Tumors
Page 157 - 182Murray TG, Ksander BREditors: Pepose JS, Holland GN, Wilhelmus KR.Mosby Publishers
Chapter: Ocular ferromagnetic hyperthermia, external beam radiotherapy, and focal chemotherapy in the treatment of murine retinoblastoma.
Page 811 - 813Murray TG, O’Brien JM, Cicciarelli N, Smith BJ, Hernandez E, Windle JJ, Ksander B, Markoe AMEditors: Franconi C, Arcangeli G, Cavaliere R.Rome, Editorgrafica
Alegret AM; Cebulla CM, Dubovy SR, Mutapcic L, Hess DJ, Murray TGEditors: Retinal Cases Brief Reports..
Chapter: Brachytherapy for Posterior Uveal Malignant Melanoma.
Schefler AC, Olsen KR, Johnson RN, Hui JI, Murray TGEditors: Albert DM, Jakobiec FA.ElsevierEdition 3,
Chapter: Issues in the diagnosis and management of small choroidal melanocytic lesions.
Page 149 - 157Scott IU, Moy CS, Murray TG, O’Brien JMEditors: O’Brien JM eds.WB Saunders Company
Chapter: Enucleation and Plaque Treatment
Olsen, KR, Murray TG, Johnson RNEditors: Albert DM, Jakobiec FA.WB Saunders CompanyEdition 2,
Chapter: Uveal Malignant Melanoma.
Page 381 - 392Aaberg TM Jr, Boldt HC, Murray TGEditors: Parrish RK II.Current Medicine, Philadelphia
Chapter: Retinoblastoma
Page 393 - 402Scott IG, Warman R, Murray TGEditors: Parrish RK II.Current Medicine, Philadelphia
Chapter: Metastatic Ocular Tumors.
Page 402 - 408Chaudhry NA, Murray TGEditors: Parrish RK II.Current Medicine, Philadelphia
Chapter: Leukemia and Lymphoma.
Page 409 - 416Tabandeh H, Murray TGEditors: Parrish RK II.Current Medicine, Philadelphia
Chapter: Choroidal Melanoma
Page 199 - 203Amirikia A, Murray TGEditors: Singh K, Smiddy WE, Lee AG, eds.Thieme, New York
Chapter: Retinoblastoma
Page 471 - 479Berrocal AM, Mavrofrides EC, Murray TGMosby Elseiver, Philadelphia
Join now to see all

Abstracts/Posters

Blood Vessel Maturation in Human Uveal Melanoma: Spatial Configuration of Endothelial Vessel Maturation and Neovasculature and Its Impact on Ocular Treatment.
Pina Y, Cebulla CM, Murray TG, Alegret A, Dubovy S, Boutrid H, Feuer W, Jockovich ME, Invest. Ophthalmol. Vis. Sc 48: Abstract nr E- 4780
Uveal Melanoma Cell-Based Vaccines Activate CD4+ T Lymphocytes That Cross-React With Primary and Metastatic Uveal Melanoma Cells.
Bosch JJ, Iheagwara UK, Murray TG, Lotem M, Ksander BR, Ostrand-Rosenberg S, Invest. Ophthalmol. Vis. Sc 48: Abstract nr E- 1945
Basic Fibroblast Growth Factor Expression in Retinoblastoma Progression and Survival.
Cebulla CM, Jockovich ME, Pina Y, Alegret A, Boutrid H, Hackam A, Feuer W, Murray TG, Invest. Ophthalmol. Vis. Sc 48: Abstract nr E- 3987
Targeting the Tumor Microenvironment as a Therapeutic Strategy for Retinoblastoma.
Murray TG, Cebulla CM, Alegret A, Pina Y, Boutrid H, Jockovich ME, Invest. Ophthalmol. Vis. Sc 48: Abstract nr E- 1585
Role of Tumor Associated Macrophages in Retinoblastoma Tumor Growth.
Jockovich ME, Diaz-Caneja J, Pina Y, Boutrid H, Cebulla CM, Murray, Invest. Ophthalmol. Vis. Sc 48: Abstract nr E- 1587
Quantitative Imaging of Eye Tumor in the Mouse Model of Retinoblastoma With Spectral-Domain Optical Coherence Tomography.
Jiao S, Ruggeri M, Wehbe H, Gregory G, Jockovich ME, Puliafito CA, Murray TG., Invest. Ophthalmol. Vis. Sc 48: Abstract nr E- 1588
Differential Induction of Apoptosis in the Treatment of LHBETATAG Retinoblastoma Following Vessel Targeting.
Alegret AM, Pina Y, Murray TG, Suarez F, Hayden B, Cebulla CM, Feuer W, Boutrid H, Jockovich ME, Invest. Ophthalmol. Vis. Sc 48: Abstract nr E- 1600
Regional Hypoxia in LHBetaTag Murine Retinoblastoma: Implication for Novel Treatments.
Boutrid H, Cebulla CM, Pina Y, Jockovich ME, Lampidis TJ, and Murray TG., Invest. Ophthalmol. Vis. Sc 48: Abstract nr E- 1601
Gelatinase Activity in Human Retinoblastoma and Choroidal Melanoma.
Cebulla CM, Jockovich ME, Bajenaru L, Murray TG, Invest. Ophthalmol. Vis. Sc 47: Abstract nr E- 2805
The Canonical Wnt Signaling Pathway Regulates the Viability of Retinoblastoma Tumor Cells.
Tell S, Yi H, Jockovich ME, Murray TG, Hackam AS, Invest. Ophthalmol. Vis. Sc 47: Abstract nr E- 2806
Blood Vessel Heterogeneity in Retinal Tumors From LHBETATAG Mice Limits Vessel Targeting Therapy.
Jockovich ME, Pina Y, Suarez F, Hernandez E, Murray TG, Invest. Ophthalmol. Vis. Sc 47: Abstract nr E- 2833
Endophthalmitis Caused by Bacillus.
Miller JJ, Flynn HW Jr., Smiddy WE, Murray TG, Scott IU, Miller D, Invest. Ophthalmol. Vis. Sc 47: Abstract nr E- 5279
Antibiotic Sensitivities and Visual Acuity Outcomes in Endophthalmitis Caused by Methacillin–Sensitive (MSSA) versus Methacillin–Resistant (MRSA) Staphylococcus aureus.
Major JC Jr., Flynn HW Jr., Miller D, Smiddy WE, Murray TG, Invest. Ophthalmol. Vis. Sc 47: Abstract nr E- 5282
Acute–Onset Endophthalmitis Following Cataract Surgery in a University Teaching Hospital (2000–2005).
Flynn HW Jr., Miller JJ, Scott IU, Smiddy WE, Murray TG, Miller D, Invest. Ophthalmol. Vis. Sc 47: Abstract nr E- 5293
Echographic Features of Melanocytoma Detected by Standard and High–Resolution Ultrasound.
Hayden BC, Schefler AC, Abramson DH, Murray TG, and Echography Study Group, Invest. Ophthalmol. Vis. Sc 47: Abstract nr E- 2260
Combined Angiostatic and Periocular Chemotherapy Using Combretastatin A4P and Carboplatin in the Treatment of LHBETATAG Transgenic Murine Model of Retinoblastoma.
Murray TG, Jockovich ME, Suarez F, Hernandez E, Feuer W, Invest. Ophthalmol. Vis. Sc 47: Abstract nr E- 2290
Taxol in the Treatment of Retinal Tumors of LH BETATAG Murine Transgenic Model of Retinoblastoma.
Suarez F, Jockovich ME, Hernandez E, Parel JM, Murray TG, Invest. Ophthalmol. Vis. Sc 47: Abstract nr E- 2801
Primary and Metastatic Uveal Melanoma Cells Genetically Modified to Express HLA–DR and CD80 Present Class II Restricted Tumor Antigens and Activate Tumor–Specific CD4+...
Bosch JJ, Thompson JA, Dissanayake SK, Murray TG, Ksander BR, Ostrand–Rosenberg S, Invest. Ophthalmol. Vis. Sc 47: Abstract nr E- 5165
Endophthalmitis Caused by Staphylococcus epidermidis: Clinical Outcomes and in vitro Antibiotic Susceptibilities.
Miller DM, Flynn HW Jr., Miller D, Scott IU, Smiddy WE, Murray TG, Venkatraman AS, . Ophthalmol. Vis. Sc 46: Abstract nr E- 3295
Posterior Juxtascleral Injection of Anecortave Acetate: Localization in Rabbit Eyes by Magnetic Resonance and Ecographic Imaging.
Jockovich ME, Moshfeghi AA, Hernandez E, Clifford PD, Murray TG, Invest. Ophthalmol. Vis. Sc 46: Abstract nr E- 482
Non–infectious Pseudohypopyon Following Intravitreal Triamcinolone Acetonide (IVTA) Injection.
Flynn HW, Moshfeghi AA, Davis JL, Kitchens JW, Murray TG, Puliafito CA, Rosenfeld PJ, Scott IU, Smiddy, Invest. Ophthalmol. Vis. Sc 46: Abstract nr E- 486
Macular Retinoblastoma: Evaluation of Tumor Control, Local Complications, and Visual Outcomes for Eyes Treated With Aggressive Chemotherapy and Laser Ablation.
Schefler AC, Cicciarelli N, Murray TG, Invest. Ophthalmol. Vis. Sc 46: Abstract nr E- 1110
Retained Lens Fragment in the New Millenium.
Gallogly P, Moore J, Scott IU, Flynn HW Jr, Smiddy WE, Murray TG, Feuer W, Invest. Ophthalmol. Vis. Sc 46: E- 5511
Delayed–onset Bleb–Associated Endophthalmitis: Clinical Features and Visual Acuity Outcomes.
Quinn CD, Flynn HF Jr, Gedde SJ, Budenz DL, Scott IU, Palmberg PF, Smiddy WE, Murray TG, Parrish RK II, Fantes FE, Invest. Ophthalmol. Vis. Sc 46: Abstract nr E- 5552
Correlation of Echographic Findings With Outcomes in Patients With Endophthalmitis.
Couvillion SS, Flynn HW Jr, Murray TG, Ehlies FJ, Miller D, Smiddy WE, Invest. Ophthalmol. Vis. Sc 46: Abstract nr E- 5568
Join now to see all

Authored Content

AAO 2023 Retina Subspecialty Day: Looking to the FutureOctober 2023
Advances in Vitreoretinal Surgical Training at AAOOctober 2019
I've Been a Vitreoretinal Surgeon for 30 Years. Surgery Is a Lifelong Learning EndeavorOctober 2019
Making Use of Pearls Learned at ASRSAugust 2019
Making Use of Pearls Learned at ASRSAugust 2019
Join now to see all